Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Total Page:16
File Type:pdf, Size:1020Kb
Supplementary Online Content Viswanathan M, Reddy S, Berkman N, et al. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. doi:10.1001/jama.2018.6537 eMethods 1. eMethods 2. eTables 1-62. eFigures 1-34. eReferences. This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 189 eMethods 1. Literature Search Strategies for Primary Literature 190 Pubmed: Screening and Treatment Number Results #1 Search ("Osteoporosis"[Mesh] OR "Fractures, Bone"[Mesh] OR "Bone Density"[Mesh]) #2 Search ("Osteoporosis"[Mesh] OR "Fractures, Bone"[Mesh] OR "Bone Density"[Mesh]) Filters: Publication date from 2009/11/01; Humans; English; Adult: 19+ years #3 Search ("Mass Screening"[Mesh] OR "Risk Assessment"[Mesh]) #4 Search (#5 AND #6) #5 Search (#5 AND #6) Filters: Systematic Reviews #6 Search (("Controlled Clinical Trial" [Publication Type] OR "Randomized Controlled Trial" [Publication Type] OR "Meta-Analysis" [Publication Type] OR "Cohort Studies"[Mesh]) OR "Case- Control Studies"[Mesh] OR "Sensitivity and Specificity"[Mesh]) #7 Search (#7 AND #9) #8 Search (#8 OR #10) #9 Search ("Osteoporosis"[Mesh] OR "Bone Density"[Mesh] OR "Calcaneus"[Mesh]) #10 Search ("Osteoporosis"[Mesh] OR "Bone Density"[Mesh] OR "Calcaneus"[Mesh])Filters: Humans; English; Adult: 19+ years #11 Search ("Osteoporosis"[Mesh] OR "Bone Density"[Mesh] OR "Calcaneus"[Mesh])Filters: Publication date from 2009/11/01; Humans; English; Adult: 19+ years #12 Search ((("Ultrasonography"[Mesh]) OR "Tomography, X-Ray Computed"[Mesh]) OR ( "Densitometry"[Mesh] OR "Absorptiometry, Photon"[Mesh] )) #13 Search (#17 AND #19) #14 Search (#17 AND #19) Filters: Systematic Reviews #15 Search (#20 AND #9) #16 Search (("Osteoporosis"[Mesh] OR "Bone Density"[Mesh])) #17 Search (("Osteoporosis"[Mesh] OR "Bone Density"[Mesh])) Filters: Publication date from 2016/01/01; Humans; English; Adult: 19+ years #18 Search ((((("Diphosphonates"[Mesh]) OR "Alendronate"[Mesh] OR "risedronic acid"[Supplementary Concept]) OR "Etidronic Acid"[Mesh]) OR "ibandronic acid"[Supplementary Concept]) OR "pamidronate"[Supplementary Concept]) OR "zoledronic acid"[Supplementary Concept] OR Bone Density Conservation Agents[mesh] "Calcium Carbonate"[Mesh] OR "Estrogen Receptor Modulators"[Mesh] OR "Selective Estrogen Receptor Modulators"[Mesh] #19 Search ((("Calcitonin"[Mesh]) OR (("Hormone Replacement Therapy"[Mesh] OR "Estrogen Replacement Therapy"[Mesh]) OR "Estradiol Congeners"[Mesh])) OR (((("Parathyroid Hormone"[Mesh]) OR "Tamoxifen"[Mesh]) OR "Teriparatide"[Mesh] OR "Raloxifene"[Mesh]) OR "Testosterone"[Mesh]) OR “RANK ligand inhibitor” OR "estropipate" [Supplementary Concept] OR "bazedoxifene" [Supplementary Concept] OR "denosumab" [Supplementary Concept]) #20 Search (#30 OR #31) #21 Search (#28 AND #32) #22 Search (#28 AND #32) Filters: Systematic Reviews #23 Search (#33 AND #9) #24 Search (#11 OR #22 OR #36) #25 Search "Mass Screening"[Mesh] OR "Risk Assessment"[Mesh] #26 Search (#1 AND #39) 191 192 6 © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 193 Pubmed: Trabecular bone score Number Results #102 Search "trabecular bone score " #105 Search ("Mass Screening"[Mesh] OR "Risk Assessment"[Mesh]) #106 Search (#102 AND #105) #107 Search (#102 AND #105) Filters: Systematic Reviews #108 Search (#102 AND #105) Schema: all Filters: Systematic Reviews #109 Search (("Controlled Clinical Trial" [Publication Type] OR "Randomized Controlled Trial" [Publication Type] OR "Meta-Analysis" [Publication Type] OR "Cohort Studies"[Mesh]) OR "Case-Control Studies"[Mesh] OR "Sensitivity and Specificity"[Mesh]) #110 Search (#102 AND #109) #114 Search (#102 AND #109) Filters: Publication date from 2009/11/01; Humans; English; Adult: 19+ years 194 195 Pubmed: Denosumab Number Search String #1 Search denosumab #4 Search "Osteoporosis"[Mesh] OR "Bone Density"[Mesh] #5 Search (#1 AND #4) #6 Search (("Controlled Clinical Trial" [Publication Type] OR "Randomized Controlled Trial" [Publication Type] OR "Meta-Analysis" [Publication Type] OR "Cohort Studies"[Mesh]) OR "Case-Control Studies"[Mesh] OR "Sensitivity and Specificity"[Mesh]) #7 Search (#5 AND #6) #8 Search (#5 AND #6) Filters: Humans #9 Search (#5 AND #6) Filters: Humans; English #10 Search (#5 AND #6) Filters: Humans; English; Adult: 19+ years 196 197 Cochrane 198 Osteoporosis AND (screening OR treatment) 199 200 Embase 201 Osteoporosis AND (screening OR treatment) 202 203 ClinicalTrials.gov 204 Osteoporosis AND (screening OR treatment) 205 206 [email protected] 207 Osteoporosis AND (screening OR treatment) 208 7 © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 209 HSRProj 210 “osteoporosis” 211 212 Cochrane Clinical Trials Registry 213 Osteoporosis AND (screening OR treatment) 214 215 WHO ICTRP 216 Osteoporosis AND (screening OR treatment) 217 8 © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 218 eMethods 2. United States Preventive Services Task Force 219 Quality Rating Criteria 220 221 Randomized controlled trials and cohort studies 222 Initial assembly of comparable groups: 223 o For randomized controlled trials: Adequate randomization, including first 224 concealment and whether potential confounders were distributed equally among 225 groups 226 o For cohort studies: Consideration of potential confounders, with either restriction or 227 measurement for adjustment in the analysis; consideration of inception cohorts 228 Maintenance of comparable groups (includes attrition, cross-overs, adherence, 229 contamination) 230 Important differential loss to followup or overall high loss to followup 231 Measurements: equal, reliable, and valid (includes masking of outcome assessment) 232 Clear definition of interventions 233 All important outcomes considered 234 Analysis: adjustment for potential confounders for cohort studies or intention-to-treat 235 analysis for randomized controlled trials 236 237 Definition of ratings based on above criteria: 238 Good: Meets all criteria: Comparable groups are assembled initially and maintained throughout 239 the study (followup ≥80%); reliable and valid measurement instruments are used and applied 240 equally to all groups; interventions are spelled out clearly; all important outcomes are 241 considered; and appropriate attention to confounders in analysis. In addition, intention-to-treat 242 analysis is used for randomized controlled trials. 243 Fair: Studies are graded “fair” if any or all of the following problems occur, without the fatal 244 flaws noted in the “poor” category below: Generally comparable groups are assembled initially, 245 but some question remains whether some (although not major) differences occurred with 246 followup; measurement instruments are acceptable (although not the best) and generally applied 247 equally; some but not all important outcomes are considered; and some but not all potential 248 confounders are accounted for. Intention-to-treat analysis is used for randomized controlled 249 trials. 250 Poor: Studies are graded “poor” if any of the following fatal flaws exists: Groups assembled 251 initially are not close to being comparable or maintained throughout the study; unreliable or 252 invalid measurement instruments are used or not applied equally among groups (including not 253 masking outcome assessment); and key confounders are given little or no attention. Intention-to- 254 treat analysis is lacking for randomized controlled trials. 9 © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 255 Source: US Preventive Services Task Force Procedure Manual. Appendix VI. Criteria for 256 Assessing Internal Validity of Individual Studies. Available at: 257 https://www.uspreventiveservicestaskforce.org/Page/Name/methods-and-processes 10 © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 258 eTable 1. Eligibility Criteria for Study Selection Crtierion Inclusion Criteria Exclusion Criteria Language Study must be published in English Study not published in English Type of research Published or unpublished original research Nonsystematic review article, letter, or editorial; articles in which results are reported elsewhere; articles with no original data Population KQs 1–3: General primary care men and women age ≥40 years KQs 1–5: without history of low trauma fractures; or endocrine disorders Majority of study likely to be related to metabolic bone disease, such as premature population has underlying ovarian failure, hypogonadism, untreated hyperthyroidism, medical condition likely to hyperparathyroidism, adrenal insufficiency or Cushing’s be related to metabolic syndrome; or chronic use of glucocorticoids medications (>5 mg/d bone disease or is already oral prednisone (or equivalent) for 3 months or longer) receiving treatment for osteoporosis or has KQs 4, 5: Majority are adults with increased fracture risk experienced a low-trauma facture Nonhuman populations Majority of study population comprises adults younger than age 40 years KQs 4, 5: Majority are adults with no increased fracture risk Study design KQs 1–3: KQ 1: Nonrandomized, Randomized,